- Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting
- Outcome of Innate Pharma’s 2024 Annual General Meeting
- Innate Pharma: Clarification Regarding SAR443579 Designation
- Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress
- Innate Pharma Reports First Quarter 2024 Business Update and Financial Results
- Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update
- Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
- Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
- Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
- Innate Pharma Announces Its Participation in Upcoming Investor Conference
More ▼
Key statistics
As of last trade, Innate Pharma SA (IPH:PAR) traded at 2.68, 27.01% above the 52 week low of 2.11 set on Apr 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.63 |
---|---|
High | 2.75 |
Low | 2.57 |
Bid | 2.67 |
Offer | 2.68 |
Previous close | 2.67 |
Average volume | 147.02k |
---|---|
Shares outstanding | 80.86m |
Free float | 60.59m |
P/E (TTM) | -- |
Market cap | 215.90m EUR |
EPS (TTM) | -0.0939 EUR |
Data delayed at least 15 minutes, as of May 24 2024 16:06 BST.
More ▼